Novo Nordisk to present new semaglutide data on ‘food noise’, body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress

Core Insights - Novo Nordisk will present 35 abstracts related to its diabetes and obesity portfolio at the EASD congress 2025, highlighting the health benefits and weight loss effects of semaglutide, along with new obesity pipeline therapies [1][3][8] Group 1: Semaglutide and Its Impact - Semaglutide has the broadest approved indications for obesity and type 2 diabetes, significantly aiding weight loss and reducing cardiovascular risks [3][14] - The drug has been associated with over 33 million patient-years of exposure since its launch in 2018, demonstrating a well-established safety and tolerability profile [14][15] Group 2: Upcoming Presentations and Events - The EASD congress will feature various presentations, including the SOUL trial on cardiovascular outcomes and the impact of semaglutide on eating behaviors and body composition [5][8][9] - An R&D investor event will be hosted by Novo Nordisk on 17 September to discuss the science behind the presented abstracts [2] Group 3: New Pipeline Therapies - Novo Nordisk is developing next-generation treatments, including cagrilintide and amycretin, aimed at better addressing the needs of individuals with diabetes and obesity [3][8][17][18] - Preliminary data from trials such as REDEFINE 1 and REDEFINE 2 will be presented, showcasing the efficacy of cagrilintide in combination with semaglutide [12][17]